John Pula, MD
Neurology · Glenview, ILNPI 1659573053
Payments from drug & device makers
Across 21 payments — averaging $138.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Eyepoint US, Inc.$125
- Bausch & Lomb Americas Inc.$96
- Regeneron Healthcare Solutions, Inc.$48
- Apellis Pharmaceuticals, Inc.$32
- Alimera Sciences, Inc.$32
- plus $169 from 7 others
What the payments were for
- Speaking & faculty fees$1,96068%
- Food & beverage$94032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 8 | $2,398 |
| Eyepoint US, Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 1 | $96 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| Alimera Sciences, Inc. | 1 | $32 |
| Glaukos Corporation | 1 | $30 |
| Aerie Pharmaceuticals, Inc. | 1 | $29 |
| Biogen | 1 | $26 |
| Shire North American Group Inc | 1 | $25 |
| Sight Sciences, Inc. | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,900 in reported general payments places this provider in the 65th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 44 | $2,424 |
| Pyridostigmine Bromide | 50 | $1,451 |
| Prednisone | 74 | $540 |
| Memantine Hcl | 21 | $221 |
| Donepezil Hcl | 17 | $186 |
| Acetazolamide | 12 | $90 |
| Gabapentin | 13 | $87 |
Paid to pharmacies, not to this prescriber.
Other neurology in Glenview
- Susan RubinGlenview$211K
- Daniel WynnNorthbrook$13.9M
- Concetta ForchettiElk Grove Village$8.5M
- Tatyana SimuniChicago$3.5M
- Danny BegaChicago$2.8M
- Thomas AlaSpringfield$2.4M
- Augusto MiravalleChicago$2.1M
- Leonard Verhagen MetmanChicago$1.8M
- Anthony RederBurr Ridge$1.6M
- Dusan StefoskiChicago$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.